Quick Answer
PUMA BIOTECHNOLOGY, INC. reported Net Income of $31.11 million for fiscal year 2025.
PUMA BIOTECHNOLOGY, INC. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | $31.11M | +2.8% |
| 2024 | $30.28M | +40.2% |
| 2023 | $21.59M | +1079450.0% |
| 2022 | $2.0K | +100.0% |
| 2021 | -$29.13M | +51.5% |
| 2020 | -$59.99M | +20.6% |
| 2019 | -$75.59M | +33.4% |
| 2018 | -$113.58M | +61.1% |
| 2017 | -$291.95M | -5.8% |
| 2016 | -$276.01M | -15.3% |
| 2015 | -$239.28M | -68.6% |
| 2014 | -$141.97M | -159.7% |
| 2013 | -$54.66M | +26.5% |
| 2012 | -$74.35M | -626.6% |
| 2011 | -$10.23M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.84M | -56.5% | +51.1% |
| June 30, 2025 | $5.86M | +229.3% | +96.9% |
| March 31, 2025 | $2.97M | +161.8% | -85.4% |
| September 30, 2024 | $20.32M | +250.5% | +548.6% |
| June 30, 2024 | -$4.53M | -313.0% | +5.9% |
| March 31, 2024 | -$4.82M | -443.7% | -183.1% |
| September 30, 2023 | $5.80M | +1710.0% | +172.6% |
| June 30, 2023 | $2.13M | -77.3% | +51.7% |
- PUMA BIOTECHNOLOGY, INC. showed an increase of +2.8% in Net Income compared to the prior fiscal year.
- Over the 2011–2025 period, PUMA BIOTECHNOLOGY, INC.’s net income has grown by 404.0% (from -$10.23 million to $31.11 million).
- The most recent figure is from PUMA BIOTECHNOLOGY, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: